- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02926092
Observational Natural History Study of Autosomal Dominant Retinitis Pigmentosa (adRP)
A Prospective, Multicenter, Longitudinal, Observational Natural History Study to Evaluate Disease Progression in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) With Misfolded Rod Opsin Mutations
연구 개요
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
Texas
-
Dallas, Texas, 미국, 75231
- Texas Retina Associates,
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- The subject has 1 documented pre-specified heterozygous rhodopsin gene (RHO) mutation confirmed by genetic testing (mutations will include P23H, T17M, and R135W).
The subject has at least 1 eye that meets all 3 of the following criteria:
- A measurable EZ area as determined by an evaluation of EZ limits on sdOCT scan, with a horizontal EZ width of greater than 3 mm
- BCVA of greater than or equal to 35 letters as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS; equivalent to 20/200 on a Snellen chart).
- A kinetic VF of greater than 10 degrees diameter in the horizontal meridian with a spot size of III
- The subject has the ability to comply with the clinical protocol, in the opinion of the investigator.
- The subject has a clear ocular media and adequate pupillary dilation in both eyes to permit adequate visual assessments in the opinion of the investigator.
- The subject has agreed to abstain from any protocol-prohibited medication(s) during study participation.
- The subject is medically stable in the opinion of the investigator and able to fulfill the protocol requirements, including the ability to complete the assessments, without placing an undue burden on the subject/subject's family.
- The subject and/or subject's parent(s) or legally authorized guardian(s) has voluntarily signed an Institutional Review Board (IRB)/ ethics committee (EC)-approved informed consent and assent form(s), as applicable, after all relevant aspects of the study have been explained and discussed with the subject and/or the subject's parent(s) or legally authorized guardian(s).
- The subject, subject's parent(s), or legally authorized guardian(s) is able to understand the nature, scope, and possible consequences of the study and agrees to comply with the protocol-defined, scheduled assessments.
Exclusion Criteria:
- The subject is participating in an interventional clinical trial or has participated in an interventional clinical trial within 90 days of screening; participation in non-interventional observational studies is permitted.
- The subject has received treatment or has been in the treatment arm of a clinical trial for gene therapy, stem cell therapy, retinal progenitor cell therapy, tissue transplantation, device or drug delivery implantation, or other similar invasive therapy.
The subject has any of the following medical conditions that will interfere with consistent follow-up over any part of the study:
- Stroke
- Severe or unstable coronary disease
- End-stage or aggressive malignancy
- General poor health or uncontrolled or severe disease (eg, cardiovascular, neurological, psychological, pulmonary,renal, hepatic, endocrine, or gastrointestinal disorders) that in the opinion of the investigator would interfere with participation in the study
The subject has any of the following ocular conditions that could interfere with or confound follow-up of disease progression:
- Glaucoma
- Diabetic retinopathy
- Choroidal neovascularization
- Retinal inflammatory disease
- Cataract worse than grade 2 (nuclear, posterior subcapsular [PSC], or cortical)
- High myopia (≥8 diopters)
- Herpes simplex virus of the eye
- Acute infection or inflammation
- Any ocular condition that in the opinion of the investigator would interfere with the ability to assess retinal morphology and functionality
- The subject has had intraocular surgery within 90 days prior to screening.
The subject currently requires the following protocol prohibited medications or has ingested such medication within 30 days of screening:
Plaquenil Thioridazine Clofazimine Deferoxamine Phenothiazine Chlorpromazine Cisplatin Valproic acid Any other drugs with known visual side effects
- The subject has 3 first- or second-degree family members already enrolled in the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
---|---|
Arm 1
Observation of progression of disease over time.
|
Observation of progression of disease over time
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Progression of disease over time in adRP patients with misfolded rod opsin mutations using ellipsoid zone (EZ) area measurements
기간: Baseline to 4 years
|
Baseline to 4 years
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Progression of disease over time in adRP patients with misfolded rod opsin mutations as measured by EZ width
기간: Baseline to 4 years
|
Baseline to 4 years
|
Progression of disease over time in adRP patients with misfolded rod opsin mutations as measured by visual fields (kinetic and static)
기간: Baseline to 4 years
|
Baseline to 4 years
|
Progression of disease over time in adRP patients with misfolded rod opsin mutations as measured by dark-adapted rod visual fields
기간: Baseline to 4 years
|
Baseline to 4 years
|
Progression of disease over time in adRP patients with misfolded rod opsin mutations as measured by electroretinography (ERG): dark- and light-adapted
기간: Baseline to 4 years
|
Baseline to 4 years
|
Progression of disease over time in adRP patients with misfolded rod opsin mutations as measured by best corrected visual acuity (BCVA)
기간: Baseline to 4 years
|
Baseline to 4 years
|
Vision-related function and quality of life as measured by 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) plus its additional items
기간: Baseline to 4 years
|
Baseline to 4 years
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Shire Director, Takeda
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .